Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Seqirus A/H7N9 Vaccine with or without MF59 Adjuvant in Healthy Adults
NCT03682120Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of A/H7N9 inactivated influenza vaccine in Avian Influenza (AI) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies at Day 43, Geometric Mean Titers (GMT) of Serum Neutralizing (Neut) Antibodies at Day 43 and 8 more. Started Nov 2018; status: completed.
02
Drugs
A/H7N9 inactivated influenza vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03682120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682120.